Sanbelat

Sanbelat

bleomycin

Manufacturer:

Sanbe

Marketer:

Sanbe
Concise Prescribing Info
Contents
Bleomycin
Indications/Uses
In combination w/ other cytostatic &/or radiotherapy in the treatment of squamous cell carcinoma of head or neck areas; Hodgkin's disease or non-Hodgkin lymphomas; testis carcinoma.
Dosage/Direction for Use
Squamous cell carcinomas IM/IV inj 10-15 U/m2 once a wk. IV infusion During 6-24 hr of 10-15 U/m2 daily in 4-7 consecutive days every 3-4 wk. Hodgkin's disease & non-Hodgkin lymphoma 5-10 U/m2 once a wk by IM/IV inj. Initial dose in lymphoma may be lowered to 2-3 U. Testis carcinomas IM/IV inj 10-15 U/m2 once or twice a wk. IV infusion During 6-24 hr of 10-15 U/m2 daily for 5-6 consecutive days every 3-4 wk. Max: 400 U. Elderly ≥80 yr 15 U/wk. Total dosage: 100 U, 70-79 yr 30 U/wk. Total dosage: 150-200 U, 60-69 yr 30-60 U/wk. Total dosage: 200-300 U, <60 yr 30-60 U/wk. Total dosage: 400 U. Impaired renal function, serum creatinine >354 micromol/L Reduce dose by >50%, serum creatinine 177-354 micromol/L Reduce dose by 50%.
Contraindications
Prior hypersensitivity or idiosyncratic reaction. Obstructive or restrictive pulmonary disorders. Ataxia telangiectasia. Pregnancy & lactation.
Special Precautions
Perform lung function tests & thorax x-rays regularly. Discontinue if coughing, dyspnoea, basal crepitations or a diffuse reticular image on thorax x-ray is observed. May impair the ability to drive or operate machines due to nausea & vomiting. Patients w/ hepatic or renal insufficiency, preexisting lung disease, previous radiation of the lungs & patients on oxygen. Ensure adequate contraception measures until 3 mth after the end of therapy for male & female patients.
Adverse Reactions
Anorexia, fatigue; inj site pain or in the tumour region, muscle & limbs, arterial hypotension & venous occlusion (IV administration); interstitial pneumonia; fever; skin & mucous membrane changes; nausea, vomiting, loss of appetite, wt loss & inflammation of the mucous membrane; severe idiosyncratic reactions; hypotension (high initial dose); minor bone marrow suppression; slight thrombocytopenia.
Drug Interactions
Increased risk of pulmonary toxicity in simultaneous administration of BCNU, mitomycin-C, cyclophosphamide & MTX. Increased toxicity of bleomycin w/ nephrotoxic subtances eg, cytostatics (cisplatin). Reduced effect of digoxin. Increased incidence & severity of pulmonary toxicity w/ previous or current radiotherapy of the thorax. Risk of pulmonary toxicity if pure oxygen is administered during operation. Reynaud's disease in patients w/ testis carcinoma who are treated w/ a combination of bleomycin & vinca alkaloids.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01DC01 - bleomycin ; Belongs to the class of other cytotoxic antibiotics. Used in the treatment of cancer.
Presentation/Packing
Form
Sanbelat powd for inj (lyo) 15 U
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in